Rebuilding the development and business platform through a capital and business alliance with JIXING and RTW
First written in FY2024-Q3. 1 of 2 entries say "Restated". Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025RestatedAnnual report
「The Company holds from CORXEL the exclusive development and commercialization rights for TMS-007 in Japan and the right to receive milestone payments and royalties for development and sales worldwide excluding Japan.」
Under its partnership with CORXEL, CORXEL conducts global development while the Company holds development and commercialization rights in Japan. - FY2024-Q3First statedAnnual report
「This alliance comprises: A) JIXING HK assuming Biogen’s contractual position under the option agreement and amending the agreement, including the Company’s acquisition of JIXING shares; B) the Company obtaining from JIXING HK, royalty-free, the development and commercialization rights in Japan for JX09, a JIXING pipeline program; and C) funds managed by RTW acquiring shares in the Company.」
The capital and business alliance included the transfer of the option agreement position from Biogen to JIXING HK, transfer of rights for TMS-007 and other programs, joint development discussions with JIXING and a capital relationship with RTW.